Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07232017 · ClinicalTrials.gov registry record
Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
A clinical trial of Hypertension (HTN), sponsored by Anita Misra-Hebert.
- Recruiting
- Registry status
- 1,520
- Enrollment target
- 1
- Study location
NCT07232017: Recruiting study of Hypertension (HTN), sponsored by Anita Misra-Hebert.
NCT07232017 is a study of Hypertension (HTN) that is actively recruiting participants, run by Anita Misra-Hebert. The registered enrollment target is 1,520 participants, below the 1,680-participant average among 3 other Hypertension (HTN) trials with a reported enrollment target (10% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07232017, a study of Hypertension (HTN), is actively recruiting participants, sponsored by Anita Misra-Hebert.
- RECRUITING
- Registry status
- 1,520 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the Implementation of Effective Hypertension Management Approaches: Cleveland Clinic program is to improve blood pressure control for patients diagnosed with hypertension (HTN) and uncontrolled blood pressure, specifically defined as a blood pressure greater than 150/95, across all Cleveland Clinic Northeast Ohio primary care practices. The project will scale up the availability of resources for treating hypertension in 56 primary care practices within the Cleveland Clinic Health System in Northern Ohio, reaching up to approximately 3800 patients. This project will utilize evidence from a randomized controlled trial by Margolis et al.(1) to build upon Cleveland Clinic's existing team-based primary care provider (PCP) collaboration with pharmacists and advanced practice providers (APP) and will use a mechanism that allows titrating blood pressure medications based on patient-recorded home blood pressure readings.
Primary Outcome
The main effectiveness finding the investigators expect to report at the end of the proposed implementation project is the change in patient systolic blood pressure from baseline to 12 months post-implementation. The expected change in systolic blood pressure based upon Margolis et al.(1) is -18mmHg. The period of evaluation will be from the time of program enrollment, with home BP measurements assessed every 2-3 weeks until the blood pressure is less than 135/85 and at 12 months. The blood pres
Conditions Studied
Interventions
- OTHER IN-HOME BP
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,520 participants |
| Start Date | 2026-01-06 |
| Est. Completion | 2029-07 |
What NCT07232017 shows while recruiting
NCT07232017 is an observational study that tracks outcomes without assigning an intervention. Its 1,520 participants enrollment target places it among the larger protocols in the corpus, below the 1,680-participant average among 3 other Hypertension (HTN) trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Hypertension (HTN) appearing as the primary indexed condition, and to 1 intervention - of which IN-HOME BP is the first listed.
NCT07232017 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07232017 about?
NCT07232017 is a clinical study titled "Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic". The primary objective of the Implementation of Effective Hypertension Management Approaches: Cleveland Clinic program is to improve blood pressure control for patients diagnosed with hypertension (HTN) and uncontrolled blood pressure, specifically defined as a blood pressure greater than 150/95, acr...
What is the current status of trial NCT07232017?
This trial is currently recruiting. The enrollment target is 1,520 participants. The study started on 2026-01-06. Estimated completion is 2029-07.
What conditions does trial NCT07232017 study?
This clinical trial studies the following conditions: Hypertension (HTN).
What interventions are being tested in trial NCT07232017?
The interventions under investigation include: IN-HOME BP (OTHER).
Who is sponsoring clinical trial NCT07232017?
This trial is sponsored by Anita Misra-Hebert, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07232017 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension (HTN)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease
RECRUITING · Phase 3
-
Study of the Progression of Chronic Cardiovascular Conditions
RECRUITING
-
Mediterranean-DASH Intervention for Neurodegenerative Delay and High-Intensity Interval Training in Adults With Hypertension
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06876714 · 1,524 participants · Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- NCT06257082 · 1,526 participants · NA
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
- NCT05633654 · 1,514 participants · Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- NCT07136623 · 1,513 participants
Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI